COMPANY PROFILE

Peroxitech

Explore full profile

Operates as a biopharmaceutical company developing PIP-2 to reverse acute lung injury

Philadelphia, United StatesFounded 2016Biotech & Life Sciences

Valuation $100–250M Last recorded · 2022

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Peroxitech

Peroxitech is an emerging biopharmaceutical company dedicated to developing and commercializing novel peptide-based therapies for acute lung injury (ALI). Leveraging groundbreaking science, Peroxitech has identified a new signaling pathway related to oxidative injury, which is pivotal in the treatment of ALI. The company primarily serves healthcare providers and institutions involved in respiratory care and lung transplantation. Operating in the biopharmaceutical market, Peroxitech's business model revolves around research and development, securing grants, and eventual commercialization of their therapeutic compounds. Revenue is generated through grants, partnerships, and future sales of their proprietary treatments. The company has received multiple NIH grants to advance their research, highlighting their innovative approach and potential impact on respiratory medicine.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2016
Headquarters: Philadelphia, United States
Employees: 1
Open positions: None listed
Dealroom signal: 54.9/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Dec 2022	$25M	$100M	Perceptive Xontogeny Venture Fund	↗
SEED✓Equity / VC	May 2021	—	—	Xontogeny	—

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Peroxitech website traffic

Latest recorded traffic for Peroxitech is 740 monthly website visits, up 1133.3% over the last three months. Peroxitech's team grew 0% over the past year.

Latest monthly visits740 3-month web change+1133.3% 1-year team growth0%

Monthly website visitsDec 2022–Mar 2025

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
NONovosteoFounded to reduce the morbidity, mortality and loss of productivity associated with bone fractures	West Lafayette, United States	Acquired	4	$7.7M	$22M
TRTandem RepeatCreating tunable, customizable and programmable protein based bioderived materials for textile, medical and cosmetic markets	Philadelphia, United States	Operational
VOxford VacmedixDevelop therapeutic agents for the treatment of cancer	Oxford, United Kingdom	Operational
VBVedanta BiosciencesPioneering rational design of drugs made of defined consortia of bacteria that are essential dwellers of the gut ecosystem	Cambridge, United States	Operational
LBLumen BioscienceDiscovers, develops and manufactures biologic drugs and vaccine candidates for several prevalent, worldwide diseases	Seattle, United States	Operational
CBCellino BiotechMaking personalized, autologous cell therapies accessible for patients	Cambridge, United States	Operational
EGEGenesisA gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues, and cells to address the global organ crisis	Cambridge, United States	Operational
KYKytopenDeveloping an automated cell engineering platform to accelerate discovery of bioengineered chemicals	Cambridge, United States	Operational